Cargando…
Novel CMKLR1 Inhibitors for Application in Demyelinating Disease
Small molecules that disrupt leukocyte trafficking have proven effective in treating patients with multiple sclerosis (MS). We previously reported that chemerin receptor chemokine-like receptor 1 (CMKLR1) is required for maximal clinical and histological experimental autoimmune encephalomyelitis (EA...
Autores principales: | Kumar, Vineet, LaJevic, Melissa, Pandrala, Mallesh, Jacobo, Sam A., Malhotra, Sanjay V., Zabel, Brian A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6509344/ https://www.ncbi.nlm.nih.gov/pubmed/31073181 http://dx.doi.org/10.1038/s41598-019-43428-8 |
Ejemplares similares
-
Designing Novel
BCR-ABL Inhibitors for Chronic Myeloid
Leukemia with Improved Cardiac Safety
por: Pandrala, Mallesh, et al.
Publicado: (2022) -
A New Nrf2 Inhibitor Enhances Chemotherapeutic Effects in Glioblastoma Cells Carrying p53 Mutations
por: Afjei, Rayhaneh, et al.
Publicado: (2022) -
The Expression and Regulation of Chemerin in the Epidermis
por: Banas, Magdalena, et al.
Publicado: (2015) -
New Selective Inhibitors of ERG Positive Prostate
Cancer: ERGi-USU-6 Salt Derivatives
por: Eldhose, Binil, et al.
Publicado: (2021) -
A Novel CMKLR1 Small Molecule Antagonist Suppresses CNS Autoimmune Inflammatory Disease
por: Graham, Kareem L., et al.
Publicado: (2014)